Submit a project

Press Coverage

Sofinnova Crossover

21 January, 2022

Tom Burt, partner at Sofinnova Partners, speaks at Edison Group’s Open House Global Healthcare Event

Related Deal lead

Related Strategy

Tom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here.

Tom Burt, Partner at Sofinnova Partners, speaks at Edison Group’s Open House Global Healthcare Event

Related Articles

2 May, 2023
Amolyt Pharma announces Phase 3 clinical trial of Eneboparatide for the treatment of hypoparathyroidism following positive end of Phase 2 Meeting with FDA
17 April, 2023
Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
5 April, 2023
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
30 March, 2023
Landmark New England Journal of Medicine publication reports positive results from PROMISE II pivotal trial showing that LimFlow System saves most patients with end-stage peripheral artery disease from major amputation
13 March, 2023
Calliditas announces primary endpoint successfully met in Phase 3 NefIgArd trial evaluating Nefecon® in IgA nephropathy
22 February, 2023
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors